SAFETY DATA SHEETS

This SDS packet was issued with item: 078064253

N/A



Revision date: 07-Dec-2006

Version: 1.2

Page 1 of 6

1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING

Pfizer Animal Health Pfizer Inc 235 East 42nd Street New York, NY 10017 Poison Control Center Phone: 1-866-531-8896 Technical Services Phone: 1-800-366-5288

Emergency telephone number: CHEMTREC (24 hours): 1-800-424-9300 Pfizer Ltd, Kent CT13 9NJ United Kingdom +00 44 (0)1304 616161

Emergency telephone number: ChemSafe (24 hours): +44 (0)208 762 8322

Material Name: Sodium Hyaluronate Injection

Trade Name:	Hylartil Vet; Hylartin V
Synonyms:	Sodium Hyaluronate Sterile Solution
Chemical Family:	Mixture
Intended Use:	Veterinary product for the treatment of osteoarthritis

2. COMPOSITION/INFORMATION ON INGREDIENTS

Hazardous

Ingredient	CAS Number	EU EINECS List	%
Sodium Hyaluronate	9067-32-7	Not listed	1
Hydrochloric Acid	7647-01-0	231-595-7	*
Sodium hydroxide	1310-73-2	215-185-5	*

Ingredient	CAS Number	EU EINECS List	%	
Disodium Hydrogen Phosphate, Dihydrate	Not Available	Not listed	*	
Sodium dihydrogen phosphate dihydrate	13472-35-0	Not listed	*	
Water for injection	7732-18-5	231-791-2	*	
Sodium chloride	7647-14-5	231-598-3	*	

Additional Information:

* Proprietary

Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.

3. HAZARDS IDENTIFICATION

Appearance:	Solution
Statement of Hazard:	Non-hazardous in accordance with international standards for workplace safety.
Additional Hazard Information: Short Term:	May cause eye and skin irritation, Not acutely toxic (based on components). Individuals sensitive to this chemical or other materials in its chemical class may develop allergic reactions.
Known Clinical Effects:	Adverse effects most commonly reported in clinical use include skin rash and gastrointestinal disturbances.
EU Indication of danger:	Not classified

Material Name:	Sodium Hyaluronate Injection	
Revision date: 07-Dec-2006		

Page 2 of 6 Version: 1.2

Note:	This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the active substance or its intermediates regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.
4. FIRST AID MEASURES	
Eye Contact:	Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.
Skin Contact:	Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.
Ingestion:	Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.
Inhalation:	Remove to fresh air and keep patient at rest. Seek medical attention immediately.
5. FIRE FIGHTING MEASURES	3
Extinguishing Media:	Use carbon dioxide, dry chemical, or water spray.
Hazardous Combustion Products:	Emits toxic fumes of carbon monoxide, carbon dioxide, and nitrogen oxides.
Fire Fighting Procedures:	During all fire fighting activities, wear appropriate protective equipment, including self- contained breathing apparatus.
Fire / Explosion Hazards:	Fine particles (such as dust and mists) may fuel fires/explosions.
6. ACCIDENTAL RELEASE ME	EASURES
Health and Safety Precautions:	Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.
Measures for Cleaning / Collecting:	Contain the source of spill if it is safe to do so. Collect spill with absorbent material. Clean spil area thoroughly.
Measures for Environmental Protections:	Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.
Additional Consideration for Large Spills:	Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.
7. HANDLING AND STORAGE	
General Handling:	Prevent inhalation, contact with eye, skin and clothing. Use with adequate ventilation. When handling, use proper personal protective equipment as specified in Section 8. Wash thoroughly after handling.
Storage Conditions:	Protect from light. Store in a refrigerated area.
Storage Temperature:	2 - 8°C

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Material Name: Sodium Hyaluronate Injection Revision date: 07-Dec-2006 Page 3 of 6 Version: 1.2

t: = 2 ppm Ceiling = 5 ppm Peak = 7.5 mg/m ³ Peak		
$2 mg/m^{3}$ $= 2 mg/m^{3} Ceiling$ $= 2 mg/m^{3} Peak$		
The purpose of the Occupational Exposure Band (OEB) classification system is to separate substances into different Hazard categories when the available data are sufficient to do so, but inadequate to establish an Occupational Exposure Limit (OEL). The OEB given is based upon an analysis of all currently available data; as such, this value may be subject to revision when new information becomes available.		
OEB2 (control exposure to the range of >100 ug/m^3 to < 1000 ug/m^3)		
Not available		
Engineering controls should be used as the primary means to control exposures. Use process containment, local exhaust ventilation, or other engineering controls to maintain airborne levels within the OEB range.		
Wear impervious gloves if skin contact is possible. Safety glasses or goggles Use protective clothing (uniforms, lab coats, disposable coveralls, etc.) in both production and laboratory areas. If airborne exposures are within or exceed the Occupational Exposure Band (OEB) range, wear an appropriate respirator with a protection factor sufficient to control exposures to the bottom of the OEB range.		

9. PHYSICAL AND CHEMICAL PROPERTIES:

Physical State: Molecular Formula: Solution Mixture Color: Molecular Weight: No data available. Mixture

10. STABILITY AND REACTIVITY

Stability: Conditions to Avoid: Incompatible Materials:

General Information:

Stable under recommended storage conditions. Exposure to light Not applicable

11. TOXICOLOGICAL INFORMATION

The information included in this section describes the potential hazards of the individual ingredients.

Acute Toxicity: (Species, Route, End Point, Dose)

Material Name: Sodium Hyaluronate Injection Revision date: 07-Dec-2006 Page 4 of 6 Version: 1.2

Sodium HyaluronateRatOralLD 50>800 mg/kgMouseOralLD 50>2400 mg/kgRatIntraperitonealLD 501770 mg/kgMouseIntraperitonealLD 501500 mg/kgRatSubcutaneousLD 50>4 g/kg

Sodium hydroxide Mouse IP LD50 40 mg/kg

Sodium chloride

 Rat
 Oral
 LD50
 3000 mg/kg

 Mouse
 Oral
 LD 50
 4000 mg/kg

 Acute Toxicity Comments:
 A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

Irritation / Sensitization: (Study Type, Species, Severity)

Sodium hydroxide

Eye IrritationRabbitSevereSkin IrritationRabbitSevere

Hydrochloric Acid

Skin Irritation Severe Eye Irritation Severe

Sodium chloride

Eye Irritation Rabbit Moderate Skin Irritation Rabbit Mild

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Sodium Hyaluronate

4 Week(s) Rat Intraperitoneal 1680 mg/kg LOAEL Blood

Sodium chloride

10 Day(s) Rat Oral 12500 mg/kg LOAEL. Kidney, Ureter, Bladder

Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

Sodium Hyaluronate

Fertility and Embryonic Development	Rat Subcutaneous	60 mg/kg NOAEL Negative
Fertility and Embryonic Development	Rabbit Intraperitonea	al 60 mg/kg NOAEL Negative
Fertility and Embryonic Development	Rat Intraperitoneal	64 mg/kg NOAEL Not Teratogenic
Fertility and Embryonic Development	Rat Subcutaneous	50 mg/kg/day NOAEL Not Teratogenic
Prenatal & Postnatal Development	Rat Subcutaneous	50 mg/kg/day NOAEL Not Teratogenic

Carcinogen Status: None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

Hydrochloric Acid		
IARC:		

Group 3

Material Name: Sodium Hyaluronate Injection Revision date: 07-Dec-2006

Page 5 of 6 Version: 1.2

12. ECOLOGICAL INFORMATION

Environmental Overview:

Environmental properties have not been investigated. Releases to the environment should be avoided.

13. DISPOSAL CONSIDERATIONS

Disposal Procedures: Dispose of waste in accordance with all applicable laws and regulations.

14. TRANSPORT INFORMATION

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

EU Indication of danger:

Not classified

OSHA Label:

Non-hazardous in accordance with international standards for workplace safety.

Canada - WHMIS: Classifications

WHMIS hazard class: None required This product has been classified in accordance with the hazard criteria of the CPR and the MSDS contains all of the information required by the CPR.

Sodium Hyaluronate Australia (AICS):

.. .

Present

Hydro	ochloric Acid	
	CERCLA/SARA 313 Emission reporting	= 1.0 % de minimis concentration acid aerosols including mists, vapors, gas, fog, and other airborne forms of any particle size
	CERCLA/SARA Hazardous Substances	= 2270 kg final RQ
	and their Reportable Quantities:	= 5000 lb final RQ
	CERCLA/SARA - Section 302 Extremely Hazardous TPQs	= 500 lb TPQ gas only
	CERCLA/SARA - Section 302 Extremely Hazardous Substances EPCRA RQs	= 5000 lb EPCRA RQ gas only
	Inventory - United States TSCA - Sect. 8(b)	T
	Australia (AICS):	Present

Material Name: Sodium Hyaluronate Injection Revision date: 07-Dec-2006

Page 6 of 6 Version: 1.2

Standard for the Uniform Scheduling	Schedule 5
for Drugs and Poisons:	Schedule 6
EU EINECS List	231-595-7
Sodium dihydrogen phosphate dihydrate	
Australia (AICS):	Present
Water for injection	
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS List	231-791-2
Sodium hydroxide	
CERCLA/SARA Hazardous Substances	= 1000 lb final RQ
and their Reportable Quantities:	= 454 kg final RQ
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
Standard for the Uniform Scheduling	Schedule 5
for Drugs and Poisons:	Schedule 6
EU EINECS List	215-185-5
Sodium chloride	
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS List	231-598-3

16. OTHER INFORMATION

Reasons for Revision:

Updated Section 3 - Hazard Identification. Updated Section 8 - Exposure Controls / Personal Protection. Updated Section 15 - Regulatory Information.

Prepared by:

Toxicology and Hazard Communication Pfizer Global Environment, Health, and Safety

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied.

End of Safety Data Sheet